Business Context and Reporting Period
Company: Oncolytics Biotech Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Accounting Standard: International Financial Reporting Standards (IFRS)
Functional Currency: Canadian Dollars (Cdn$)
Oncolytics Biotech Inc. is a development-stage biopharmaceutical company focused on the discovery and development of pharmaceutical products for the treatment of cancers, specifically those with an activated Ras pathway. The company's primary product candidate is REOLYSIN®, a therapeutic reovirus. The company has no commercial product sales and relies on equity financing to fund its operations.
Key Financial Metrics
| Metric | 2014 (Cdn$) | 2013 (Cdn$) |
|---|---|---|
| Revenues | — | — |
| Net Loss | (18,619,335) | (23,532,647) |
| Loss Per Share (Basic & Diluted) | (0.21) | (0.28) |
| Total Assets | 17,193,190 | 28,222,027 |
| Cash and Cash Equivalents | 14,152,825 | 25,220,328 |
| Short-Term Investments | 2,031,685 | 2,001,644 |
| Total Current Liabilities | 3,373,997 | 6,008,661 |
| Shareholders' Equity | 13,819,193 | 22,213,366 |
| Accumulated Deficit | (249,966,335) | (231,347,000) |
| Outstanding Common Shares | 93,512,494 | 84,803,818 |
Operating Expenses: Research and development expenses were $13,824,252 in 2014, compared to $18,506,064 in 2013. Operating expenses were $4,998,694 in 2014, compared to $5,392,660 in 2013.
Financing Activities: The company raised net cash proceeds of $9,044,492 in 2014 through the issuance of common shares via a Share Purchase Agreement and an "At the Market" equity distribution agreement.
Material Changes Versus Prior Period
- Improved Net Loss: The net loss decreased by approximately $4.9 million (21%) from 2013 to 2014, primarily due to reduced research and development and operating expenses.
- Cash Position: Cash and cash equivalents decreased by approximately $11.1 million, reflecting a net cash outflow from operating activities of $19.7 million, partially offset by financing proceeds.
- Share Capital: The number of outstanding common shares increased by 8,708,676 (10.3%) due to equity issuances in 2014.
- Liabilities: Total current liabilities decreased by approximately $2.6 million, driven by a reduction in accounts payable and accrued liabilities.
- Warrants: All outstanding warrants expired during 2014, resulting in a $376,892 reclassification to contributed surplus.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance: The company does not expect to generate significant revenues until, if and when, REOLYSIN® becomes commercially viable. Management anticipates continuing to incur significant losses in 2015 and the foreseeable future. The company expects to fund future operations through existing cash resources, additional equity financings, or strategic partnerships.
Key Risks:
- Development Risk: REOLYSIN® is in the research and development stage. There is no assurance that clinical trials will demonstrate safety and efficacy or that regulatory approval will be obtained.
- Liquidity Risk: The company has a history of losses and requires additional financing to fund ongoing operations and clinical trials. Failure to secure funding could force a reduction in R&D activities.
- Listing Compliance: The company received a notice from NASDAQ regarding its common shares trading below the $1.00 minimum bid price requirement. The company has until April 27, 2015, to regain compliance or risk delisting.
- Manufacturing Dependence: The company relies on third-party contract manufacturers for the production of REOLYSIN®. Disruptions in supply could delay clinical trials.
- PFIC Status: The company believes it is classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which may have adverse tax consequences for U.S. shareholders.
Contingencies: The company has contingent obligations including a potential $1.0 million milestone payment to former shareholders upon regulatory approval of REOLYSIN® and royalty payments based on future sales. Additionally, the company has committed to payments totaling $4,176,218 in 2015 for clinical trial and manufacturing activities.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $16.2 million in cash and short-term investments to fund operations through the completion of planned clinical trials in 2015.
- NASDAQ Compliance: Monitor the company's ability to regain compliance with the $1.00 minimum bid price requirement by April 27, 2015, to avoid delisting.
- Clinical Trial Progress: Review the status and results of ongoing Phase II and Phase III clinical trials for REOLYSIN® across various cancer indications (e.g., melanoma, lung cancer, pancreatic cancer).
- Financing Needs: Assess the likelihood and terms of future equity issuances required to bridge the funding gap, given the company's lack of operating revenue.
- Contingent Liabilities: Understand the potential financial impact of the $1.0 million milestone payment and future royalty obligations upon commercialization.